Table 3.
Anti-phospholipid antibodies in patients with Crohn’s disease, ulcerative colitis, and healthy controls n (%)
| CD (n = 265) | UC (n = 186) | HC (n = 103) | |
| Anti-β2-GPI IgG | 5 (1.9) | 4 (2.2) | 2 (1.9) |
| Anti-β2-GPI IgM | 8 (3.0) | 12 (6.5) | 3 (2.9) |
| Anti-β2-GPI IgA | 7 (2.6) | 7 (3.8) | 3 (2.9) |
| Any anti-β2-GPI | 19 (7.2) | 18 (9.7) | 8 (7.8) |
| ACA IgG | 27 (10.2)bd | 4 (2.2)d | 2 (1.9)b |
| ACA IgM | 8 (3.0) | 4 (2.2) | 1 (1.0) |
| ACA IgA | 51 (19.2)bd | 1 (0.5)d | 0 (0.0)b |
| Any ACA | 62 (23.4)bd | 9 (4.8)d | 3 (2.9)b |
| Anti-PS/PT IgG | 20 (7.5) | 9 (4.8) | 9 (8.7) |
| Anti-PS/PT IgM | 25 (9.4)bc | 8 (4.3)c | 1 (1.0)b |
| Anti-PS/PT IgA | 24 (9.1)c | 7 (3.8)c | 9 (8.7) |
| Any anti-PS/PT | 54 (20.4)d | 19 (10.2)d | 16 (15.5) |
b
P < 0.01, CD vs controls;
c
P < 0.05,
d
P < 0.01, CD vs UC. Using χ2-test with Yates correction. APLA: Antiphospholipid antibodies; β2-GPI: Beta2-glycoprotein-I; ACA: Anti-cardiolipin antibody; PS/PT: Phosphatidylserine/prothrombin complex; CD: Crohn’s disease; UC: Ulcerative colitis.